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Abstract 
Cytochrome P-450 (CYP) are the most common drug metabolizing enzymes and are abundantly expressed 
in liver apart from kidney, lungs, intestine, brain etc. Their expression levels change with physiological 
conditions and disease states. The expression of these CYPs is less in human foetus and neonates 
compared to adults, which results in lower clearance of xenobiotics in infants and neonates compared to 
adults. Hepatocytes are the cells which are largely used to study these CYPs. We have isolated 
hepatocytes from aborted foetus to study the metabolism of six probe substrates: phenacetin, diclofenac, 
S-mephenytoin, dextromethorphan, nifedipine and testosterone. The results obtained show the 
expression of various CYPs (CYP1A2, CYP2C19, CYP2C9, CYP2D6, and CYP3A4) in human foetus and their 
involvement in metabolism of CYP probe substrates. 
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Introduction 
The role of Cytochromes P450 (CYP) mediated metabolism is well appreciated in the drug discovery 
setup, over the last few decades much emphasis has been laid on how different drugs are handled by the 
CYPs. CYPs are one of the major source of variability in pharmacokinetics (PK) and pharmacodynamics (PD) 
of the drugs [1]. The CYPs are widely distributed and expressed in different organs including, liver, intestine, 
lungs, kidney, placenta, brain etc. The highest expression levels are observed in liver, and the major ones to 
be expressed in liver are CYPs 3A4, 2C9, 2C8, 2E1, and 1A2 [2]. These five isoforms are responsible for the 
biotransformation of many of the drugs in market which makes up to 80 % of the total drugs in clinical use. 
Expression of these CYP enzymes depends on varied factors including sex, age, disease states, etc [3]. The 
mechanism of these CYP isoforms and their contribution towards drug-drug interactions leading to either 
changes in label or complete withdrawal from the market has been well understood [4]. Even though 
thorough investigations of these CYPs including their polymorphism led to relatively safer prescription 
practices [5], involvement of fetal metabolism still remains highly disparaged [6-9]. Role of CYP enzymes in 
clearance of drugs from foetus and neonates is explored since early 70’s, but the lack of microsomes and 
hepatocytes of fetal and neonatal origin has greatly limited our understanding of the drug behaviour in 
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foetus and neonates. Furthermore, lack of complete knowledge of adverse events related to drugs and 
scant data of PK parameters during pregnancy leads to either cautious prescription or complete avoidance 
of many drugs [10-12]. Advances in drug metabolism, drug transport and drug-drug interactions in human 
foetus will greatly benefit the patients and clinicians alike [13]. Hepatocytes are considered as one of the 
better in vitro tools to study metabolism [14, 15], therefore we explored the metabolic stability of six probe 
substrates: phenacetin (CYP1A2), diclofenac (CYP2C9), S-mephenytoin (CYP2C19), dextromethorphan 
(CYP2D6), nifedipine (CYP3A4) and testosterone (CYP3A4) in hepatocytes of fetal origin [16].  
Experimental  
Chemicals and Reagents  
Diclofenac, 4-hydroxydiclofenac, dextromethorphan, dextrorphan, phenacetin, paracetamol, S-
mephenytoin, 4-hydroxymephenytoin, nifedipine, oxidized nifedipine, testosterone, 6β-
hydroxytestosterone, celecoxib, DMSO (dimethyl sulfoxide), DMEM (Dulbecco’s modified eagles medium), 
PBS (phosphate buffer saline) were obtained from Sigma Aldrich (St. Louis, MO USA). HPLC (high 
performance liquid chromatography) grade acetonitrile and methanol were obtained from E Merck India 
Limited (Mumbai, India), and all the other chemicals were used of highest quality available. 
Hepatocytes isolation, in vitro culture and characterization 
Human fetal livers were obtained from spontaneous abortions from 10-14 weeks of gestation. All donors 
of the fetus were thoroughly screened serologically for syphilis, toxoplasmosis, rubella, hepatitis B and C, 
human immunodeficiency virus 1, cytomegalovirus, parvovirus, and herpes simplex types 1 and 2. Liver 
cells were isolated using two-step collagenase perfusion method as described by Habibullah et al [17]. 
Briefly, resected liver from the aborted fetuses were collected under sterile conditions within 2h of the 
termination of pregnancy and then cut into thin slice (1-2 mm thickness). Thereafter, each fetal liver was 
digested with 0.02 % collagenase type IV (SigmaAldrich, St. Louis, USA) containing penicillin G (10 U/ml, 
streptomycin10 U/ml, amphoteracin B (0.025 μg/ml) at 37 °C for 30 min. Single cell suspension of liver was 
collected by centrifugation at 250 g and then washed with sterile phosphate buffered saline (PBS  pH 7.4). 
The viability of the cells was measured using trypan blue method. Cells showing more than 80 % viability 
were used for the metabolism experiments. 
Metabolism Studies 
1 mL of cell mixture containing 1 million cells per ml were transferred to a 12 well cell culture plate 
(costar) and 10 µL of test compound (in DMSO water) was added to maintain a final volume of DMSO below 
0.2% v/v. The incubation plate was then transferred to an incubator set at 37 °C with a relative humidity of 
95 % and CO2 (carbon dioxide) at 5 %. The samples were incubated for 2 h and at the end of 2 h viability of 
the cells was checked using an aliquot of 20 µL mixture. The incubation was terminated using 4 mL of 
acetonitrile containing internal standard celecoxib (1 mg/mL), vortex mixed for 2 mins and centrifuged at 
3000 rpm on a table top centrifuge (Remi Instruments, India). The supernatant was transferred to clean 
glass tube and the contents were dried under gentle stream of nitrogen using a multivap evaporator set at 
40 °C (N-evap, Orgiinomation, Berlin, MA, USA). The residue was reconstituted in 200 µL of mobile phase 
(A:B, 1:1) and 100 µL of this solution was injected into the HPLC. For 0 h samples, acetonitrile was added 
prior to addition of test compound to prevent the reaction followed by the above described sample 
preparation method. 
Each of the test compounds was incubated in triplicates; the area of the drug was divided by the area of 
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the internal standard to get the area ratio. The area ratio obtained from 0 h was considered as 100 % and 
the area ratio of 2 h sample was calculated to get the metabolic stability of the test compound. Each of the 
experiment was conducted at least three times on different days with new fetal hepatocytes. 
Instrumentation and Chromatographic Conditions 
HPLC analysis was performed using the previously published method [18]. In brief, HPLC system 
consisted of a Waters 2695 alliance separation module attached with a Waters 2996 photodiode array 
(PDA) detector, the instrument was setup to detect a range of 190-400 nm. A C18 Inertsil ODS 3V column 
(4.6 x 250 mm, 5 µm, GL Sciences, Inc., Tokyo, Japan) was used for the analysis. A ternary mobile phase 
gradient system was used consisting of A (0.01 M ammonium acetate, pH 5.0: acetonitrile; 90:10), B (0.01 M 
ammonium acetate buffer, pH 5.0: acetonitrile; 5:95) and C- 0.01 mM ammonium acetate buffer, pH 
5.0:methanol; 5:95), the total run time was 40 minutes with gradient flow shown in Table 1, analysis was 
performed by integrating the peak area of the individual peaks at UV (Ultraviolet) maximum as described 
by Rao et al [18] and shown in Table 2. Similarly, the peak area counts of internal standard was integrated. 
The area counts of test compound was divided by the area counts obtained from the internal standard (IS) 
within the same analytical run to get the area ratios which were used to calculate the % depletion of the 
parent compound over a period of 2 h.   
Data Analysis  
The data was plotted using Prism software (GraphPad Software Inc., San Diego, CA), all data are 
presented as the mean of each group ± S.E.M. (standard error of mean) as indicated in the figure legend. 
Metabolic stability was calculated using the substrate depletion approach [19], using the equation below 
[20]. 
 
Ratio of substrate in test sample
%  Substrate remained in test sample    = *100
Ratio of substrate in control sample
 
Results and Discussion 
Isolation of hepatocytes from the fetal liver resulted in 80 % viable cell, isolation resulting in less than 80 
% viability, or cells showing visible signs of deterioration were not considered for metabolism experiments. 
Figure 1 shows microscopic image of the 14 week old healthy hepatocytes. Six of the commonly used probe 
substrates, phenacetin at a concentration of 100 µM as a substrate of CYP1A2 [21], diclofenac at a 
concentration of 25 µM as a substrate of CYP2C9 [22], S-mephenytoin at a concentration of 5 µM as a 
substrate of CYP2C19 [23], dextromethorphan at a concentration of 50 µM as a substrate of CYP2D6 [24], 
nifedipine at a concentration of 5 µM as a substrate of CYP3A4 and testosterone at a concentration of 120 
µM as a substrate of CYP3A4 [25], were used to evaluate the contribution towards fetal metabolism. These 
concentrations were chosen based on in-house Km values generated using liver microsomes and 
hepatocytes and with reference to the concentrations suggested by the FDA (Food and Drug 
Administration) guidance for drug interaction studies 2006 [16, 26]. Each of the marker reaction was 
monitored by comparing the UV peak of metabolite with the analytical standard of each metabolite. The 
peak area of all the test compound was obtained at lambda max (λ) of individual well resolved 
chromatographic peaks devoid of interference. Table 2 shows UV max and retention time (RT) of all 
compounds. The following reactions were monitored, phenacetin-O-deethylation as marker reaction of 
CYP1A2, diclofenac-4-hydroxylation as marker reaction of CYP2C9, S-mephenytoin-4-hydroxylation as 
marker reaction of CYP2C19, dextromethorphan-O-demethylation as marker reaction of CYP2D6, nifedipine 
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oxidation as marker reaction of CYP3A4, and  testosterone 6 β-hydroxylation as marker reaction of CYP3A4 
to confirm the metabolism by the respective CYPs. Comparison of area ration between 0 h which was 
considered as 100 % against 2 h samples resulted in, 68.2 ± 8.13 %, 50.5 ± 4.29 %, 79.8 ± 6.11 %, 72.2 ± 6.12 
%, 1.32 ± 0.21 %, and 4.26 ± 0.92 % respectively for phenacetin, diclofenac, S-mephenytoin, 
dextromethorphan, nifedipine and testosterone respectively. The results are shown as mean of three 
independent experiments with standard error of mean. Depletion of all the substrates indicates maturation 
and involvement of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in fetal liver. CYP3A4 showed 
maximum activity, resulting in more than 90 % depletion of both the CYP 3A4 substrates nifedipine as well 
as testosterone, followed by 50 % depletion of diclofenac, 32 % depletion of phenacetin, 28 % depletion of 
dextromethorphan and 20 % depletion of S-mephenytoin. These results clearly suggest the maturation and 
involvement of 5 different CYPs in metabolism through human foetus. Due to limitation in availability of 
fetal tissue other substrates cannot be evaluated. Furthermore, studies to evaluate the kinetic parameters 
to generate Km and Vmax of each CYP using a probe substrate will be beneficial for the regulatory authorities 
and clinicians to optimize the dose and prevent drug-drug interactions in pregnant women and neonates. 
Table 1. Gradient time program for HPLC with UV detection with ternary gradient 
mobile phase, method was reproduced from Rao et. al. [18]. 
Time, min Flow, mL/min %A %B %C 
0 1 100 0 0 
2 1 90 0 10 
9 1 50 20 30 
12 1 50 25 25 
25 1 30 50 20 
28 1 10 85 5 
35 1 10 85 5 
36 1 100 0 0 
40 1 100 0 0 
A =90:10:: 10 µM ammonium acetate: acetonitrile, B =5:95:: 10 µM ammonium acetate: 
acetonitrile, and C =5:95:: 10 µM ammonium acetate: methanol 
 
Table 2. Retention times and UV max (λ max) of CYP probe substrates, their 
metabolites and internal standard. 
Compound UV extracted, nm, Retention Time, min 
Phenacetin 240 14.1 
Paracetamol 240 7.1 
Diclofenac 280 24.9 
4-Hydrxoydiclofenac 280 18.7 
S-mephenytoin 250 15.9 
4-Hydroxymephenytoin 250 11.5 
Dextromethorphan 277 14.3 
Dextrorphan 277 10.3 
Nifedipine 240 22.9 
Hydroxynifedipine 240 21.2 
Testosterone 240 24.4 
6β-Hydroxytestosterone 240 15.7 
Celecoxib 250 30.1 
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Figure 1. A 10 x microscopic image of the well differentiated hepatocytes of human origin, obtained from 14 


















Figure 2. Metabolism of six CYP probe substrates, the bars represent mean of percent remaining of the drug 
after 2 h obtained from three independent experiments, the bars represent standard error of mean. 
Conclusions 
In conclusion, fetal hepatocytes were successfully isolated from different subjects with viability of 
greater than 80% using earlier reported method [17]. These cells were used to perform the metabolism 
studies of six probe CYP substrates, using parent depletion approach [19, 27]. The results obtained by the 
commonly used substrate depletion approach [19, 28, 29] prove differentiation, maturation and 
involvement of five CYPs (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) in clearance of phenacetin, 
diclofenac, S-mepheytoin, dextromethorphan, nifedipine and testosterone from the fetal liver. 
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suggesting well differentiation of CYP3A4 as compared to other CYPs which resulted in lesser depletion of 
other substrates. This study was limited by the availability of fetal hepatocytes to calculate the intrinsic 
clearance (Clint) commonly used to represent in vitro metabolism [30, 31], and determine the mRNA content 
of CYP450 for head on comparison with adult hepatocytes [32], which will be helpful in designing the doses 
of different drugs in pregnant women and neonates.  
 
Note: Abdul Naveed Shaik’s current affiliation: Center for Pharmacometric and Systems Pharmacology, 
University of Florida, Orlando FL 
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